KSA has mapped out an ambitious plan to transform its economy and improve the lives of its citizens – Vision 2030. ​

For the pharma industry, this means reducing reliance on imported drug products, developing specialised therapies and expanding domestic manufacturing capacity.​

It also means leveraging digital technologies to increase healthcare efficiency, access and effectiveness. The Healthcare Sector Transformation Program is revolutionizing the Kingdom's healthcare system to be more comprehensive, effective, and integrated than ever before.​

The Future Theatre will bring together regional players and government representatives to share the strategic vision for the future of Middle East pharma, forge new partnerships and establish the region as a leading pharma hub.​

The Future Theatre agenda spans three days, each with a distinct theme:​

• The KSA Opportunity, delves into Saudi Arabia's healthcare transformation and pharmaceutical industry, exploring domestic manufacturing, investment opportunities, and regulatory landscapes. ​
  
  
• Manufacturing Transformation explores manufacturing excellence, tech transfer, healthcare infrastructure, partnerships, large and small molecule capabilities in emerging markets.  ​
  
  
• Digital Futures will explore digital innovation, AI potential in the Middle East pharma industry, connectivity in the medical device market, and the reshaping of healthcare digital models.​

The National Biotech Strategy will establish Saudi Arabia as the leading biotech hub in MENA by 2030, and globally by 2040.  The Strategy will contribute over $34.6 billion to non-oil GDP by 2040, and create 11,000 high-quality, innovative job opportunities by 2030.​

There is enormous potential for biologics development across the Middle East, but the market is pre-mature and requires knowledge transfer, technical expertise and strategic partnerships to achieve its goals.​

CPHI Middle East is uniquely positioned to support the development of a new biotech eco-system.​

The Next-Gen Bio agenda spans three days, each exploring a different facet of the large molecule value chain:​
 

• Biopharma Innovation and State of the Market, what is the current state of play with biotech development, and the vision for achieving goals outlined in the National Biotech Strategy? A series of keynotes and panel discussions will explore the future of biotech ecosystems and lessons from the global biologics industry. ​
  
  
• Global Biopharma Trends featuring insights on talent acquisition, regulatory environments, transformative medicine like mRNA technology, and meeting oncology needs in the Middle East. ​
  
  
• The National Biotech Strategy, delving into vaccine development, genomics' importance in the region, plant optimization , and packaging and logistic challenges in the bio sector. ​

Incentivizing and investing in R&D is essential to diversifying the portfolio of locally produced pharmaceuticals and transforming the Middle East from an import, to an innovator market.​

​

Pharma innovation is a complex ecosystem which requires the buy in of many different stakeholders, including governments and policymakers, regulatory bodies, academic institutions, R&D organizations, entrepreneurs, start-ups and pharmaceutical companies. These stakeholders should work together to facilitate drug discovery and development.​

The Innovation Theatre agenda will explore research, innovation and entrepreneurship over three days, including: ​
 

• Start-Up Ecosystems, including sessions on building a framework which supports entrepreneurs, venture capital investment strategies, and pitch sessions from our exhibiting start-ups.​
  
  
• Academia's role in Vision 2030, how can R&D be incentivized across the region? ​
  
  
• Creating a framework for sustainable innovation, innovation leadership awards, case studies on product pipelines, and panel discussions on social well-being and adaptation in KSA. ​

The event will provide a platform for networking, knowledge sharing, and showcasing innovative ideas and solutions.​

Identifying and engaging with the right partner, product or solution to accelerate discovery, development or manufacturing is a process which it’s essential to get right.  ​

For emerging markets, engaging partners for knowledge transfer, technical expertise, and best practices related to the development, manufacturing, and quality control of pharmaceutical products is essential for success.​

The Discovery Theatre agenda unfolds over three days, with a focus on discovering the products, partnerships, solutions and insights needed to accelerate growth.​
 

• Case studies from international companies who have established a footprint in KSA, understanding local regulations, building relationships, and navigating entry obstacles. ​
  
  
• Commercial presentations on products, solutions and technologies from leading pharma companies.​
  
  
• Regional insights from across the broader Middle East and Africa region.​

The Vision Theatre agenda will explore the ideas and innovations driving the next generation of pharmaceutical advancements, including:

• Sessions focusing on how to chart a path towards a diverse, innovative and sustainable pharma future
• Woman in pharma programme with highlights on the strengths and importance of female leaders in the pharma industry 
• How the API industry in Saudi Arabia is at a pivotal stage, with strong government support, increasing healthcare needs, and a strategic push under Vision 2030.